NCCN Guidelines for Patients® | Stage III Breast Cancer
Table of Contents Table of Contents
Previous Page  57 / 88 Next Page
Information
Show Menu
Previous Page 57 / 88 Next Page
Page Background

55

NCCN Guidelines for Patients

®

:

Breast Cancer – Locally Advanced (STAGE III)

Version 1.2017

6

Endocrine therapy

Treatment guide

Guide 10. Options for premenopause

Initial and sequential treatment

Extended treatment

• Tamoxifen for 5 years ± ovarian

suppression or ablation

ª

If in premenopause:

• Consider taking tamoxifen for another 5 years, or

• Stop taking endocrine therapy

ª

If in postmenopause:

• Take aromatase inhibitors for 5 years, or

• Consider taking tamoxifen for another 5 years

• Aromatase inhibitor for 5 years + ovarian suppression or ablation

Guide 11. Options for postmenopause

Initial, sequential, and extended treatment

• Aromatase inhibitor for 5 years then consider taking for another 5 years

• Aromatase inhibitor for 2–3 years then tamoxifen to complete 5 years of endocrine therapy

• Tamoxifen for 2–3 years then an aromatase inhibitor to complete 5 years of endocrine therapy

• Tamoxifen for 2–3 years then an aromatase inhibitor taken for up to 5 years

• Tamoxifen for 4.5–6 years then an aromatase inhibitor for 5 years

• Tamoxifen for 4.5–6 years then consider continuing to complete 10 years of endocrine therapy

• Tamoxifen for 5 years if aromatase inhibitors aren’t an option

• Consider tamoxifen for up to 10 years if aromatase inhibitors aren’t an option